JAGUAR HEALTH, INC. Convertible Notes Payable, Current
JAGUAR HEALTH, INC. (JAGX) had Convertible Notes Payable, Current of $11.15 million as of 2019-03-31, per its 10-Q filed 2019-05-21.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities › Notes Payable, Current
us-gaap:ConvertibleNotesPayableCurrent · last filed 2020-04-03
- 2019-03-31: Convertible Notes Payable, Current $11.15M.
- 2018-12-31: Convertible Notes Payable, Current $11.24M.
- 2018-09-30: Convertible Notes Payable, Current $1.06M.
- 2018-06-30: Convertible Notes Payable, Current $660.02K.
| Period end | Convertible Notes Payable, Current |
|---|---|
| 2019-03-31 | $11.15M 10-Q · filed 2019-05-21 |
| 2018-12-31 | $11.24M 10-K · filed 2020-04-03 |
| 2018-09-30 | $1.06M 10-Q · filed 2018-11-19 |
| 2018-06-30 | $660.02K 10-Q · filed 2018-08-13 |
| 2018-03-31 | $690.68K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $2.67M 10-K · filed 2019-04-10 |
| 2017-09-30 | $3.21M 10-Q · filed 2017-11-20 |
| 2017-06-30 | $1.78M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $150.00K 10-Q/A · filed 2017-06-23 |
| 2016-12-31 | $150.00K 10-K · filed 2018-04-09 |
| 2016-09-30 | $150.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $150.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $150.00K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $150.00K 10-K · filed 2017-02-15 |
| 2015-09-30 | $150.00K 10-Q · filed 2015-11-13 |
| 2015-06-30 | $123.21K 10-Q · filed 2015-08-13 |
| 2015-03-31 | $786.15K 10-Q · filed 2015-06-26 |
| 2014-12-31 | $424.67K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |